Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...
The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.
MedPage Today on MSN
Lower metastasis risk in very high-risk prostate cancer with intensified treatment
Adding darolutamide to ADT and RT improved metastasis-free survival, but questions persist ...
Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...
Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at ...
The FDA previously approved FoundationOne CDx, which uses a tumor tissue sample, and FoundationOne Liquid CDx, which uses a ...
An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction ...
Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States who have been diagnosed with prostate ...
1. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results